Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. [electronic resource]
Producer: 20180423Description: 35468 p. digitalISSN:- 2045-2322
- Animals
- Apigenin -- pharmacology
- Apoptosis -- drug effects
- Carcinoma, Non-Small-Cell Lung -- genetics
- Caspases -- metabolism
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Disease Models, Animal
- Drug Synergism
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Lung Neoplasms -- genetics
- MAP Kinase Signaling System
- Mice
- Mitochondria -- drug effects
- NF-kappa B -- metabolism
- Phosphatidylinositol 3-Kinases -- metabolism
- Proto-Oncogene Proteins c-akt -- metabolism
- Receptors, TNF-Related Apoptosis-Inducing Ligand -- genetics
- Signal Transduction -- drug effects
- TNF-Related Apoptosis-Inducing Ligand -- pharmacology
- Tumor Stem Cell Assay
- Tumor Suppressor Protein p53 -- metabolism
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.